Streetbeat News

Stock Prices

VRTX

HC Wainwright & Co. analyst Andrew Fein has maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $390 to $397.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:24 pm

NKE

Citigroup analyst Paul Lejuez has upgraded Nike (NYSE:NKE) from Neutral to Buy and increased the price target from $100 to $135, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:22 pm

DIS

HTLD

NXT

OLMA

Insiders at four companies, including Walt Disney (DIS), Heartland Express (HTLD), Nextracker (NXT), and Olema Pharmaceuticals (OLMA), have recently made significant stock purchases. These insider trades suggest confidence in the companies' prospects. Nextracker's CEO acquired shares after positive quarterly results, while Olema Pharmaceuticals' owner invested following interim clinical study results. Walt Disney's director purchased shares amid a new streaming integration, and Heartland Express' owner bought a substantial number of shares despite weak quarterly results.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 12:17 pm

TMO

Citigroup analyst Patrick Donnelly has reaffirmed a Buy rating on Thermo Fisher Scientific (NYSE:TMO) and increased the price target from $530 to $575, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:13 pm

QDEL

Citigroup analyst Patrick Donnelly has downgraded QuidelOrtho (NASDAQ:QDEL) from Buy to Neutral and reduced the price target from $95 to $72.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:12 pm

LXEO

Lexeo Therapeutics (NASDAQ:LXEO) reported a wider Q3 loss of $(12.36) per share compared to $(10.38) per share in the same quarter last year. The company completed its IPO in November 2023, raising $111.5 million, which is expected to fund operations into Q4 2025.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:10 pm

APLS

Apellis Pharmaceuticals presented new data at the ASH Annual Meeting showing that its drug EMPAVELI (Pegcetacoplan) provided long-term control of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:10 pm

GFS

SLAB

John Hollister, CFO of Silicon Labs (NASDAQ:SLAB), is set to join GlobalFoundries as its new CFO. Mark Mauldin, currently the chief accounting officer at Silicon Labs, will become the interim CFO after the transition, which is expected to be completed by February 2, 2024. Silicon Labs is actively searching for a new CFO to help scale the company's position in the Internet of Things market.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:05 pm

GLPI

Mizuho analyst Haendel St. Juste has downgraded Gaming and Leisure Properties (GLPI) from Buy to Neutral and reduced the price target from $50 to $47.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:05 pm

AAPL

SSNLF

Samsung (OTC:SSNLF) is reorganizing its display unit to concentrate on foldable screens and extended reality microdisplays, aiming to lead in these technologies. The move is a response to competition from Oppo and OnePlus in the foldable phone market and to prepare for Apple's (NASDAQ:AAPL) entry into foldable Macs and iPads, as well as the anticipated release of Apple's Vision Pro headset. Samsung plans to make foldables mainstream and secure differentiated technologies, with results expected to show by the Galaxy Z Fold 6 release.

Portfolio Pulse from Benzinga Neuro

December 11, 2023 | 12:05 pm